Basel Healthtech fund successfully closed
The venture capital firm MTIP has announced the successful closing of its FUND II. It is one of the first funds to invest in innovative European Healthtech firms in the growth phase.
Christoph Kausch, Managing Partner and Co-Founder of MTIP (img: MTIP)
MTIP has completed the fundraising phase for its second fund. As the Basel-based private equity firm announced on December 7, it raised a total of 250 million US dollars in capital commitments under its MTIP Fund II instead of the original target of 225 million US dollars.
The “dark green”, sustainability-focused fund is one of the first of its kind to specialize in the Healthtech sector. It invests in digital health companies and digitally-connected medical technology firms with the aim of supporting international expansion plans. “We are excited to announce the successful closing of our second fund and continue our mission to build the Healthtech leaders of tomorrow”, explains Christoph Kausch, Managing Partner at MTIP, in the press release.
New and existing investors in the fund included institutional investors, pension funds, family offices, hospitals, foundations and the health insurance firm Sanitas, further details of which can be found in the press release. Andreas Schönenberger, CEO of Sanitas, praised MTIP’s “unique expertise in Healthtech” that allows it to foster innovation “in this under-served private equity sector”.
MTIP writes further in the press release that it has already made successful investments in five companies as part of its MTIP Fund II: Oviva, Trialbee, Koa Health, Intelligencia and Mediktor.
Share this article
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More